银屑病生物制剂临床应答预测因素的系统综述与荟萃分析
结果显示高龄、高BMI、合并症及特殊部位受累与较差应答相关,而家族史阳性与更好结局相关。这些基线因素有助于基于表型的风险分层和治疗选择。
要点
- 高龄、高BMI、合并症及特殊部位受累是生物制剂应答差的负性预测因素。
- 阳性家族史与更好的生物制剂应答显著相关。
- 基线可获取的因素可用于银屑病生物制剂治疗的风险分层。
核心结论
- 高龄、较高合并症负担、肥胖及特殊部位受累与银屑病患者生物制剂应答较差相关,而家族史与更好结局相关。
主要发现
- 完全清除的负性预测因素包括:年龄较大(OR 0.99,95% CI 0.98-0.99,p < 0.001)、较高体重指数(OR 0.94,95% CI 0.92-0.97,p < 0.001)、合并症(OR 0.75,95% CI 0.63-0.9,p = 0.002)及特殊部位受累(OR 0.71,95% CI 0.56-0.89,p = 0.003)。
- 阳性家族史(OR 1.42,95% CI 1.18-1.71,p < 0.001)为与更好结局相关的显著预测因素。
- 其他分析变量未观察到显著关联。
临床怎么用
- 可利用年龄、BMI、合并症、特殊部位受累及家族史等基线因素对银屑病患者进行表型风险分层,辅助生物制剂治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic therapies have revolutionized psoriasis management, yet inter-individual response varies significantly and reliable predictors of complete skin clearance remain unclear. OBJECTIVES: This study aimed to identify prognostic predictors of biologic efficacy in patients with psoriasis through a systematic review and meta-analysis. METHODS: We systematically searched four databases (from their inception to January 28, 2026). Studies were screened and data extracted per predefined criteria; quality was assessed using the Newcastle-Ottawa Scale (NOS), and analyses were performed in Stata 15.0. RESULTS: Thirty studies (n = 13,902) were included. Negative predictors of clearance included older age (odds ratio [OR] 0.99, 95% CI 0.98-0.99, p < 0.001), higher body mass index (OR 0.94, 95% CI 0.92-0.97, p < 0.001), comorbidities (OR 0.75, 95% CI 0.63-0.9, p = 0.002), and involvement of special areas (OR 0.71, 95% CI 0.56-0.89, p = 0.003). Conversely, a positive family history (OR 1.42, 95% CI 1.18-1.71, p < 0.001) emerged as a significant predictor associated with better outcomes. No significant associations were observed for other analysed variables. CONCLUSIONS: Older age, higher comorbidity burden, obesity, and special-site involvement are associated with poorer biologic response in psoriasis, whereas family history is associated with better outcomes. These readily available baseline factors facilitate phenotype-based risk stratification and may guide treatment selection in clinical practice.
引用
- Mao X, Meng S, Wu P, et al. Predictors of clinical response to biologics in psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2026. PMID: 41995334. doi:10.1111/jdv.70462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。